Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2005-01-18
2005-01-18
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S204100, C424S230100, C435S235100, C435S325000, C536S023720
Reexamination Certificate
active
06843992
ABSTRACT:
The invention provides a plurality of peptides (and immunologically functional variants thereof) which are immunogenic epitopes recognized by CD8+class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus (HCMV) infection. The peptides are capable of activating CTLs and CTLps in the absence of active viral replication, and thus are useful for eliciting a cellular immune response against HCMV by normal and immunodeficient subjects. Peptide and lipopeptide vaccines, with and without adjuvants, also are disclosed. Cellular vaccines comprising the peptides form a further embodiment of this invention.
REFERENCES:
patent: 5075213 (1991-12-01), Pande et al.
patent: 5405940 (1995-04-01), Boon et al.
patent: 5470730 (1995-11-01), Greenberg et al.
patent: 5736142 (1998-04-01), Sette et al.
patent: 6074645 (2000-06-01), Diamond et al.
patent: WO 9205794 (1992-04-01), None
patent: WO 9400150 (1994-01-01), None
patent: WO 9606929 (1996-03-01), None
patent: WO 9740165 (1997-10-01), None
patent: WO 9826074 (1998-06-01), None
patent: WO 9919349 (1999-04-01), None
patent: WO 0075180 (2000-12-01), None
Moldoveanu et al., “CpG DNA, a Novel Immune Enhancer for Systemic and Mucosal Immunization with Influenza Virus,”Vaccine, 16:11/12:1216-1224, 1998.
Alexander et al., “Development of High Potency Universal DR-Restricted Helper Epitopes by Modification of High Affinity DR-Blocking Peptides,”Immunity1:751-761, Dec. 1994.
Bernhard et al., “Cytotoxic T Lymphocytes from HLA-A2 Transgenic Mice Specific for HLA-A2 Expressed on Human Cells,”J. Exp. Med. 168:1157-1162, Sep. 1988.
Berzofsky et al., “Construction of peptides Encompassing Multideterminant Clusters of Human Immunodeficiency Virus Envelope to Induce in Vitro T Cell Responses in Mice and Humans of Multiple MHC Types,”The J. of Clinical Investigation88:876-884, Sep. 1991.
Boppana et al., “Recognition of Human Cytomegalovirus Gene Products by HCMV-specific Cytotoxic T Cells,”Virology222:293-296, 1996.
Borysiewicz et al., “Relative Frequency of Stage-specific CTL Recognizing the 72-kD Immediate Early Protein and Glycoprotein B Expressed by Recombinant Vaccinia Viruses,”J. Exp. Med. 168:919-931, Sep. 1988.
Brouwenstijn et al., “Definition of Unique and Shared T-Cell Defined Tumor Antigens in Human Renal Cell Carcinoma,”J. of Immunotherapy21(6):427-434, 1998.
Chujoh et al., “The role of anchor residues in the binding of peptides to HLA-A*1101 molecules,”Tissue Antigens52:501-509, 1998.
Clay et al., “Changes in the Fine Specificity of gp100(209-217)-Reactive T Cells in Patients Following Vaccination with a Peptide Modified at an HLA-A2.1 Anchor Residue,”J. of Immunology, 1749-1755, 1999.
Greenberg et al. “Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded in vitro”Annals of the New York Academy of Sciences636:184-195, 1991.
Gyulai et al., “Cytotoxic T Lymphocyte (CTL) Responses to Human Cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in Healthy Individuals: Reevaluation of Prevalence of IE1-Specific CTLs,”The J. of Infectious Diseases181:1537-46, 2000.
Ishioka et al. “Utilization of MHC Class I transgenic mice for development of minigen DNA vaccines encoding multiple HLA-restricted CTL epitopes”J. Immunology162:3915-3925, 1999.
Kern et al., “Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overtapping pentadecapeptides,”Eur. J. Immunol. 30:1676-1682, 2000.
Kern et al., “Target Structures of the CD8+-T Cell Response to Human Cytomegalovirus: the 72 Kilodalton Major Immediate-Early Protein Revisited,”J. of Virology73(10):8179-8184, Oct. 1999.
Lipford et al. “Peptide Engineering Allows Cytotoxic T-cell Vaccination Against Human jPapilloma Virus Tumour Antigen, E6”Immunology84:298-303, 1995.
Livingston et al. “Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans”J. Immunology162:3088-3095, 1999.
Ohlin et al. “Characterization of human monoclonal antibodies directed against the pp65-kD matrix antigen of human cytomegalovirus”Clin. Exp. Immunol. 84:508-514, 1991.
Oseroff et al. “Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL eiptope responses”Vaccine16(8):823-833, 1998.
Panina-Bordignon et al., “Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells,”Eur. J. Immunol. 19:2237-2242, 1989.
Retiére et al., “Generation of cytomegalovirus-Specific Human T-Lymphocyte Clones by Using Autologous B-Lymphoblastoid Cells with Stable Expression of pp65 or IE1 Proteins: a Tool to Study the Fine Specificity of the Antiviral Response,”J. of Virology74(9):3948-3952, May 2000.
Riddell et al. “Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression”J. Immunology146(8):2795-2804, Apr. 15, 1991.
Rüger et al. “Primary structure and transcription of the genes coding for the two virion phosphoproteins pp65 and pp71 of human cytomegalovirus”J. Virology61(2):446-453 Feb. 1987.
Schild et al., “Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells,”Eur. J. Immunol. 21:2649-2654, 1991.
Theobald et al., “Targeting p53 as a general tumor antigen,”Proc. Natl. Acad. Sci. USA92:11993-11997, Dec. 1995.
Tsunoda et al. “Lipopeptide particles as the immunologically active component of CTL inducing vaccines,”Vaccine17:675-685, 1999.
Vierboom et al. “Peptide Vaccination with an Anchor-Replaced CTL Epitope Protects Against Human Papillomavirus Type 16-induced Tumors Expressing with Wild-Type Epitope,”J. Immunotherapy219(6):399-408, 1998.
Wentworth et al., “Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice,”Eur. J. Immunol. 26:97-101, 1996.
Wentworth et al. “In Vitro induction of Primary, Antigen-Specific CTL from Human Peripheral Blood Mononuclear Cells Stimulated with Synthetic Peptides,”Molecular Immunology32(9):603-612, 1995.
Quinnan et al., “HLA-Restricted T-Lymphocyte and Non-T-Lymphocyte Cytotoxic Responses Correlate with Recovery from Cytomegalovirus Infection in Bone-Marrow-Transplant Recipients,”The New England Journal of Medicine307(1): 7-13, 1982.
Borysiewicz et al., “Human Cytomegalovirus-Specific Cytotoxic T Lymphocytes: Requirements for in vitro Generation and Specificity,”Eur. J. Immunol. 13:804-809, 1983.
Clark et al., “Isolation and Partial Chemical Characterization of a 64,000-Dalton Glycoprotein of Human Cytomegalovirus,”Journal of Virology49(1):279-282, 1984.
Forman et al., “A 64,000 Dalton Matrix Protein of Human Cytomegalovirus Induces In Vitro Immune Responses Similar to Those of Whole Viral Antigen”,The Journal of Immunology134(5):3391-3395, 1985.
Meyers et al., “Risk Factors for Cytomegalovirus infection After Human Marrow Transplantation,”The Journal of Infecious Diseases153(3):478-488, 1986.
Miller et al., “Retrovirus-Mediated Gene Transfer into Human Skin Fibroblasts”, Mar. 1988 Meeting at Cold Spring Harbor.
Borysiewicz et al., “Relative Frequency of Stage-specific CTL Recognizing the 72-kD Immediate Early Protein and Glycoprotein B Expressed by Recombinant Vaccinia Viruses,”J. Exp. Med. 168:919-931, 1988.
Townsend et al., “Recognitionof Influenza Virus Proteins by Cytotoxic T Lymphocytes”,Phil. Trans. R. Soc. Lond. B. 323:527-533, 1989.
Ge
City of Hope
Rothwell Figg Ernst & Manbeck
Salimi Ali R.
LandOfFree
Immuno-reactive peptide CTL epitopes of human cytomegalovirus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immuno-reactive peptide CTL epitopes of human cytomegalovirus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immuno-reactive peptide CTL epitopes of human cytomegalovirus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3371867